Don’t know if this was posted $ 1 billion deal LRRK2

[ParlePark]

michaeljfox.org/news/news-c...

[Gioc]

if they move all this money it bodes well, thanks Parlepark very interesting.

[ParlePark in reply to Gioc]

People like this usually put money where their mouth is. Hard nut to crack but this is surely encouraging.

[Patrickk]

Bydureon, a repurposed Type 2 Diabetes drug is now in third-stage trials in UK for stopping Parkinson's in its tracks -- results expected 2023. Testing -- mice, open label, double blind -- has been going on for 10 years and it has been positive every time.

scienceofparkinsons.com/201...

I have found some symptom relief (don't have very bad case) with Tumeric & black pepper (pepper makes it bioavailable) -- recommended by a doctor.

According to a very sensitive test, Homeostasis Model Assessment for Insulin Resistance (HOMA-IR), 2/3 of Parkinson's patients are supposed to be insulin resistant. I read somewhere that IR may be treated with Bydureon (Exanatide) but I can't now find the link. Just something that might get us one step closer to Bydureon.

scienceofparkinsons.com/201...

cureparkinsons.org.uk/news/...

PS. I took Bydureon for five years before going into remission on Type 2 Diabetes. Funny if it helped me with both.

[WinnieThePoo]

It was posted already. But it's still good news. Doubley so as i have Biogen shares in my 401k

[sharoncrayn]

LRRK2 is a gene in the brain. Mutations of LRRK2 generally cause what is commonly referred to as "famlilial" PD although it supposedly also causes idiopathic PD based Pitt University study... Five(5) gene mutations including LRRK2 supposedly cause 10-15% of PD, LRRK2 less than 3%.

The collaborative research trials will focus on manipulation of the LRRK2 mutation which is a relatively narrow goal. If they are successful, we might see something in the 2024 time frame.

Basically it is a Denali pharma project using its DNL201 (versus its 151) drug which has successfully completed a non-registered Phase 1a and 1b with healthy participants (no PD in 1a, PD in 1b).

***Phase 1b had several questionable adverse events.

Also, undergoing a trial in the Netherlands.

A large international observational trial related to LRRK2 is in progress.

Sharon